The State of Innovation in Drug Development
Abstract
The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by regulatory authorities, the time to discover and develop drugs, and the cost of drug development. Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many drugs fail during clinical trials, especially phase III, largely due to lack of clinical efficacy and/or unacceptable toxicity.
“Many of the drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, 4,5 largely due to the lack of clinical efficacy and/or unacceptable toxicity. 6,7”
From Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors (2014) · cites this paper as [7]
The citation lists haven’t been fetched yet
References 9 · Cited by 276
- Authors
- Kola, I.
- Corresponding author
- Kola, I
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2008-02
- Volume
- 83
- Issue
- 2
- Pages
- 227-230
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2139694010
- Cited by
- 276
- References
- 9
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 11 · 2022: 6 · 2021: 12 · 2020: 7 · 2019: 15 · 2018: 9 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 25 · 2012: 31
- FWCI
- 60.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- pharmaceutical industry, research and development, regulatory challenges, drug development costs, time to market, payers, drug registration
- MeSH terms
- Animals, Diffusion of Innovation, Drug Industry, Humans, Legislation, Drug, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Drug Costs, Drug Approval, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
